Literature DB >> 12100368

Long-term follow-up of myasthenia gravis patients with hyperthyroidism.

D Ratanakorn1, A Vejjajiva.   

Abstract

OBJECTIVE: To access clinical characteristics and treatment outcome of myasthenia gravis (MG) patients with hyperthyroidism (HT).
MATERIALS AND METHODS: The clinical characteristics of 51 MG patients with HT were studied. The treatment outcome was analysed in 34 patients, comparing high-dosage prednisolone (HDP) (group IS), HDP and/or immunosuppressants with antithyroid drugs (group IS + antiHThyr), antithyroid drugs (group antiHThyr), and thymectomy.
RESULTS: The prevalence of HT in MG was 17.5%. Group IS showed higher remission of both diseases compared with group antiHThyr, but not with group IS + antiHThyr. Remission of HT and relapse of both diseases showed no difference among the three groups. Ten patients who had thymectomies had a lower relapse of MG but not of HT, whilst remission of both diseases was no different to 24 non-thymectomy patients.
CONCLUSION: This study showed a high prevalence of HT in Thai MG. HDP alone can induce remission of both diseases without difference in relapse. Thymectomy lowers MG relapse further but has no influence on HT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100368     DOI: 10.1034/j.1600-0404.2002.01191.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

1.  Myasthenia Gravis Presenting as Persistent Unilateral Ptosis with Facial Droop.

Authors:  Sean K Golden; Chris J Reiff; Chris J Painter; Michael D Repplinger
Journal:  J Emerg Med       Date:  2015-03-19       Impact factor: 1.484

2.  Clinical profile of 80-year-old and older thyroid eye disease patients.

Authors:  Niv Levy; Hana Leiba; Klara Landau; Ofira Zloto; Ruth Huna-Baron
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-26       Impact factor: 3.535

3.  Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course.

Authors:  Justyna Kubiszewska; Beata Szyluk; Piotr Szczudlik; Zbigniew Bartoszewicz; Małgorzata Dutkiewicz; Maksymilian Bielecki; Tomasz Bednarczuk; Anna Kostera-Pruszczyk
Journal:  Brain Behav       Date:  2016-08-04       Impact factor: 2.708

4.  [Hypothyroidism and myasthenia: a case study].

Authors:  Houda Salhi; Farida Ajdi
Journal:  Pan Afr Med J       Date:  2019-09-30

5.  Ocular myasthenia gravis in a setting of thyrotoxicosis.

Authors:  Sarabjeet Chhabra; B C Pruthvi
Journal:  Indian J Endocrinol Metab       Date:  2013-03

Review 6.  Complicating autoimmune diseases in myasthenia gravis: a review.

Authors:  Aliona Nacu; Jintana Bunpan Andersen; Vitalie Lisnic; Jone Furlund Owe; Nils Erik Gilhus
Journal:  Autoimmunity       Date:  2015-04-27       Impact factor: 2.815

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.